Now that the IP is in the hands of TIS, the company becomes worth taking over for a potential predator.
Even if this doesn't happen, the company still has to raise cash to complete additional trials for CE Mark and they want to start FDA trials this year. All this costs money, which they don't have.
Realistically, the transfer of IP was one of the few ways they could easily bolster the SP in the short term. That will help with the cap raise as they won't be diluting the SP.
The other option is now they own the IP, they can partner with a big player - a bit like farming out a Oil and Gas prospect. They can sell a proportion of the IP, in return for "free carry" on FDA trials.
There is still no path forward for how they are going to achieve CE Mark, no path forward for how they are going to achieve FDA approval.
But having the IP in their hands gives them a ton more options.
TIS Price at posting:
6.8¢ Sentiment: None Disclosure: Not Held
